Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) Receives $28.34 Average Target Price from Analysts

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) has been assigned a consensus rating of “Buy” from the ten brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $28.47.

Several equities research analysts have weighed in on EIGR shares. Wedbush reissued an “outperform” rating and set a $74.00 price objective on shares of Tempur Sealy International in a research note on Tuesday, June 18th. LADENBURG THALM/SH SH reissued a “buy” rating and set a $28.00 price objective on shares of Eiger Biopharmaceuticals in a research note on Tuesday, June 18th. ValuEngine cut Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Zacks Investment Research cut Exponent from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Citigroup reissued a “hold” rating on shares of AbbVie in a research note on Wednesday, June 26th.

Shares of NASDAQ:EIGR traded up $0.24 during mid-day trading on Tuesday, reaching $11.16. The stock had a trading volume of 82,769 shares, compared to its average volume of 182,412. The company has a debt-to-equity ratio of 0.62, a quick ratio of 8.16 and a current ratio of 8.16. The firm has a market cap of $214.94 million, a P/E ratio of -2.92 and a beta of 1.07. Eiger Biopharmaceuticals has a 1 year low of $8.40 and a 1 year high of $15.33. The business has a 50 day moving average of $10.69.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last posted its earnings results on Thursday, May 9th. The biotechnology company reported ($0.90) EPS for the quarter, topping analysts’ consensus estimates of ($0.95) by $0.05. As a group, equities research analysts anticipate that Eiger Biopharmaceuticals will post -2.55 EPS for the current year.

In related news, Director Thomas John Dietz acquired 5,000 shares of Eiger Biopharmaceuticals stock in a transaction on Monday, April 22nd. The shares were bought at an average cost of $11.05 per share, with a total value of $55,250.00. Following the completion of the purchase, the director now directly owns 15,000 shares of the company’s stock, valued at approximately $165,750. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have acquired 7,250 shares of company stock worth $80,130 over the last three months. 5.80% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. RA Capital Management LLC purchased a new stake in shares of Eiger Biopharmaceuticals in the fourth quarter valued at approximately $24,541,000. 683 Capital Management LLC lifted its holdings in Eiger Biopharmaceuticals by 155.1% during the fourth quarter. 683 Capital Management LLC now owns 1,610,529 shares of the biotechnology company’s stock worth $16,363,000 after buying an additional 979,296 shares during the period. BlackRock Inc. lifted its holdings in Eiger Biopharmaceuticals by 108.6% during the fourth quarter. BlackRock Inc. now owns 468,678 shares of the biotechnology company’s stock worth $4,761,000 after buying an additional 244,028 shares during the period. Telemetry Investments L.L.C. lifted its holdings in Eiger Biopharmaceuticals by 301.1% during the fourth quarter. Telemetry Investments L.L.C. now owns 152,406 shares of the biotechnology company’s stock worth $1,548,000 after buying an additional 114,406 shares during the period. Finally, Broadfin Capital LLC purchased a new stake in Eiger Biopharmaceuticals during the fourth quarter worth $1,456,000. 80.03% of the stock is currently owned by hedge funds and other institutional investors.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Recommended Story: Conference Calls

Analyst Recommendations for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.